The patent relates to the use of IBR-Snowflake for promoting skin benefits, with the Israel-based company claiming it smoothes skin, reduces wrinkles and slows down skin ageing.
IBR-Snowflake relies on an aqueous extract from summer snowflake bulbs and is based on the Dormins technology platform that uses natural extracts from plants in their dormant stage to slow down cell proliferation.
The patent relates to these Leucojum extracts, particularly to aqueous extracts of Leucojum bulbs effective in inhibiting contraction of muscle cells or tissues.
It also covers them as anti-oxidants or compositions that act as a relaxant of cutaneous muscles effective in treating and preventing wrinkles, fine lines and oxidative damages of the skin.
"This patent is an additional support and protection of this excellent active ingredient of ours already shown to be effective as anti-wrinkle ingredient with additional skin benefits of anti-ageing, boost of natural skin defense by enhancing SOD expression as well as lightening and evening the skin tone,” says IBR Vice-President of Business Development Dr von Oppen-Bezalel.
It joins the series of patents, applications and trademarks in IBR's portfolio including its Dormins technology and the colourless carotenoids, phytoene and phytofluene.
"The expansion of IBR's patent portfolio promotes our global market growth and strengthen our positioning as a market leader and provider of innovative active ingredients," adds Oppen-Bezalel.
Tried and tested
Trials were initially carried out on the product years ago in France on 21 healthy female volunteers aged between 42 – 64, to test the efficacy of the product.
The trial was double blind placebo controlled with randomized application, and saw one group apply IBR-Snowflake in a 2% concentration in a cream for 28 days.
The analysis of the test results was carried out using Skin Image Analyser and Primos, showing that the 2% dose reduces micro relief furrows by 30% and a 15% decrease in medium depth wrinkles.